DAIC

MARCH 28, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).

Atrial Fibrillation 110

Atrial Fibrillation AFIB Ablation Pulmonary 110

Circulation: Arrhythmia and Electrophysiology

DECEMBER 21, 2023

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Inflammation may promote atrial fibrillation (AF) recurrence after catheter ablation. The first dose of the study drug was administered within 4 hours before ablation. 1.61];P=0.92) or at 3 months following ablation (14% versus 15%; HR, 0.95 [95% CI, 0.45–2.02];P=0.89).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Chest Pain Atrial Flutter 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. There were no incidences of adverse event fistula, diaphragmatic paralysis, MI, pericarditis, thromboembolism, PV stenosis, transient ischemic attack, or death.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Outcomes 40